Comparative Studies of Methansulfonic Acid Esters and Other Antitumor Agents on Immune Response

Abstract

Oral or intraperitoneal administration of bis(3-methylsulfonyloxypropyl)amine p-toluenesulfonate (864-T) and N-methyl-N, N-bis(3-methylsulfonyloxypropyl)amine 4, 4'-biphenyldisulfonate (838-D) for 3 consecutive days before or after immunization suppressed the number of 19S hemolysin plaque-forming cells (HPFC) in the spleen as well as the circulating antibodies, hemagglutinin and hemolysin, of mice on day 4 after immunization with sheep red blood cells. In single administration, the maximum inhibition was found on day 0 in 864-T and 838-D, on day 2 in cyclophosphamide, and on day 3 in busulfan. 864-T and 838-D were classified in the different type from cyclophosphamide or busulfan. Seven-S HPFC were not suppressed by 864-T, 838-D, nitrogen mustard N-oxide, busulfan, or 6-mercaptopurine in the administration for 3 consecutive days from day 0 or from day 4, and only cyclophosphamide inhibited it when administered from day 4. 864-T and 838-D did not affect the carbon clearance in mice.